Literature DB >> 315314

Pharmacokinetics of fenbufen in man.

G Cuisinaud, J Legheand, G Llorca, C Belkahia, E Lejeune, J Sassard.   

Abstract

The pharmacokinetics of fenbufen (3,4-biphenylcarbonyl proprionic acid) a new antiinflammatory agent, and its metabolites, gamma-hydroxy-4-biphenylbutyric acid and 4-biphenylacetic acid have been studied after oral administration to seven patients with rheumatoid arthritis. Fenbufen was administered as a single oral dose of 600 mg in hard gelatine capsules. A specific, sensitive gas chromatographic method was used to measure the concentration of the three compounds. A linear two-compartment open model appeared suitable to describe the course of the plasma level of fenbufen with time. This compound appeared in the blood after a lag time of 0.45 h and the peak plasma concentration of 5.97 micrograms/ml was observed after 1.19 h. The half-life of plasma disappearance was 10.26 h for fenbufen and 10.07 h and at 9.95 for metabolites II and III, respectively.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315314     DOI: 10.1007/bf00644968

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Analgesic value of fenbufen in postoperative patients. A comparative oral analgesic study of fenbufen, aspirin, and placebo.

Authors:  A Sunshine
Journal:  J Clin Pharmacol       Date:  1975 Aug-Sep       Impact factor: 3.126

2.  Some studies on the metabolism of BDH 7538 in animals and man with particular reference to its anti-inflammatory properties.

Authors:  R A Franklin
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

3.  Fenbufen, a new anti-inflammatory analgesic: synthesis and structure-activity relationships of analogs.

Authors:  R G Child; A C Osterberg; A E Sloboda; A S Tomcufcik
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

4.  A double-blind comparative study of the analgesic effects of fenbufen, codeine, aspirin, propoxyphene and placebo.

Authors:  A Coutinho; J Bonelli; P C de Carvalho
Journal:  Curr Ther Res Clin Exp       Date:  1976-01

5.  Fenbufen--a new nonsteroidal anti-inflammatory agent: comparison with phenylbutazone in rheumatoid arthritis.

Authors:  I De Salcedo
Journal:  Curr Ther Res Clin Exp       Date:  1975-08

6.  Gas chromatographic determination of 3-(4-biphenylylcarbonyl)propionic acid (fenbufen) and two metabolites in human plasma.

Authors:  G Cuisinaud; J Legheand; C Belkahia; J Sassard
Journal:  J Chromatogr       Date:  1978-02-01

7.  The pharmacology of fenbufen, 3-(4-biphenylylcarbonyl)propionic acid, and 4-biphenylacetic acid, interesting antiinflammatory-analgesic agents.

Authors:  A E Sloboda; A C Osterberg
Journal:  Inflammation       Date:  1976-12       Impact factor: 4.092

  7 in total
  6 in total

1.  The disposition of biphenylacetic acid following topical application.

Authors:  M Dawson; C M McGee; J H Vine; P Nash; T R Watson; P M Brooks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Does fenbufen have a large distribution volume or is it subject to extensive presystemic elimination?

Authors:  R K Verbeeck; S M Wallace
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 4.  Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

5.  Pharmacokinetics of tenoxicam in patients with impaired renal function.

Authors:  F F Horber; T W Guentert; E Weidekamm; P Heizmann; C Descoeudres; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.